Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
04 Dezember 2024 - 1:30PM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the
“Company”), a clinical-stage pharmaceutical company developing
targeted radiotherapeutics with advanced platform technologies for
central nervous system (CNS) cancers, will present data at the 2024
San Antonio Breast Cancer Symposium, December 10-13, 2024 in San
Antonio, Texas.
Presentation:
Title |
|
Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the
treatment of leptomeningeal metastases (LM): Update on Phase 1 dose
escalation (Abstract Number: SESS-2271, Presentation ID:
PS14-01) |
|
|
|
Presenter |
|
Andrew Brenner, M.D., Ph.D., Professor and Kolitz / Zachry Endowed
Chair Neuro-Oncology Research; Co-Leader, Experimental and
Developmental Therapeutics Program, University of Texas Health,
Science Center at San Antonio |
|
|
|
Date/Time |
|
Friday, 13 December 2024 7:30-8:30 a.m. CST |
|
|
|
Location |
|
Stars at Night Ballroom 3-4, Henry B. Gonzalez Convention
Center |
About Leptomeningeal Metastases
(LM)
LM is a rare complication of cancer in which the
primary cancer spreads to the cerebrospinal fluid (CSF) and
leptomeninges surrounding the brain and spinal cord. All
malignancies originating from solid tumors, primary brain tumors,
or hematological malignancies have this LM complication potential
with breast cancer as the most common cancer linked to LM, with
3-5% of breast cancer patients developing LM. Additionally, lung
cancer, GI cancers and melanoma can also spread to the CSF and
result in LM. LM occurs in approximately 5% of people with cancer
and is usually terminal with 1-year and 2-year survival of just 7%
and 3%, respectively. The incidence of LM is on the rise, partly
because cancer patients are living longer and partly because many
standard chemotherapies cannot reach sufficient concentrations in
the spinal fluid to kill the tumor cells, yet there are no
FDA-approved therapies specifically for LM patients, who often
succumb to this complication within weeks to several months, if
untreated.
About Rhenium (186Re)
obisbemeda
Rhenium (186Re) obisbemeda is a novel injectable
radiotherapy specifically formulated to deliver direct targeted
high dose radiation in CNS tumors in a safe, effective, and
convenient manner to optimize patient outcomes. Rhenium (186Re)
obisbemeda has the potential to reduce off target risks and improve
outcomes for CNS cancer patients, versus currently approved
therapies, with a more targeted and potent radiation dose.
Rhenium-186 is an ideal radioisotope for CNS therapeutic
applications due to its short half-life, beta energy for destroying
cancerous tissue, and gamma energy for real-time imaging. Rhenium
(186Re) obisbemeda is being evaluated for the treatment of
recurrent glioblastoma and leptomeningeal metastases in the
ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is
supported by an award from the National Cancer Institute (NCI),
part of the U.S. National Institutes of Health (NIH), and
ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer
Prevention & Research Institute of Texas (CPRIT).
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage
pharmaceutical company developing targeted radiotherapeutics for
difficult-to-treat cancers of the central nervous system with the
potential to enhance clinical outcomes for patients. Combining
image-guided local beta radiation and targeted drug delivery
approaches, the Company is advancing a pipeline of product
candidates with lead programs in recurrent glioblastoma (GBM) and
leptomeningeal metastases (LM). The Company has built a supply
chain through strategic partnerships that enable the development,
manufacturing, and future potential commercialization of its
products. Plus Therapeutics is led by an experienced and dedicated
leadership team and has operations in key cancer clinical
development hubs including Austin and San Antonio, Texas. For more
information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding
Forward-Looking Statements
This presentation contains statements that may
be deemed “forward-looking statements” within the meaning of U.S.
securities laws, including statements regarding clinical trials,
expected operations and upcoming developments. All statements in
this press release other than statements of historical fact are
forward-looking statements. These forward-looking statements may be
identified by future verbs, as well as terms such as “potential,”
and similar expressions or the negatives thereof. Such statements
are based upon certain assumptions and assessments made by
management in light of their experience and their perception of
historical trends, current conditions, expected future developments
and other factors they believe to be appropriate. These statements
include, without limitation, statements regarding the potential
promise of rhenium (186Re) obisbemeda including the ability of
rhenium (186Re) obisbemeda to safely and effectively deliver
radiation directly to the tumor at high doses, and the potential
commercialization of the Company’s products.
The forward-looking statements included in this
press release could differ materially from those expressed or
implied by these forward-looking statements because of risks,
uncertainties, and other factors that include, but are not limited
to, the following: the early stage of the Company’s product
candidates and therapies; the results of the Company’s research and
development activities, including uncertainties relating to the
clinical trials of its product candidates and therapies; the
Company’s liquidity and capital resources and its ability to raise
additional cash to fund its operations in the near term and long
term, on terms acceptable to us or at all; the outcome of the
Company’s partnering/licensing efforts; risks associated with laws
or regulatory requirements applicable to the Company, including the
ability to come into compliance with The Nasdaq Capital Market
listing requirements; market conditions; product performance;
litigation or potential litigation; competition within the cancer
diagnostics and therapeutics field; ability to develop and protect
proprietary intellectual property or obtain licenses to
intellectual property developed by others on commercially
reasonable and competitive terms; manufacturing and supply chain
risks; and material security breach or cybersecurity
attack affecting the Company’s operations or property. This list of
risks, uncertainties, and other factors is not complete. Plus
Therapeutics discusses some of these matters more fully, as well as
certain risk factors that could affect Plus Therapeutics’ business,
financial condition, results of operations, and prospects, in its
reports filed with the SEC, including Plus Therapeutics’ annual
report on Form 10-K for the fiscal year ended December 31, 2023,
quarterly reports on Form 10-Q, and current reports on Form 8-K.
These filings are available for review through the SEC’s website at
www.sec.gov. Any or all forward-looking statements Plus
Therapeutics makes may turn out to be wrong and can be affected by
inaccurate assumptions Plus Therapeutics might make or by known or
unknown risks, uncertainties, and other factors, including those
identified in this press release. Accordingly, you should not place
undue reliance on the forward-looking statements made in this press
release, which speak only as of its date. The Company assumes no
responsibility to update or revise any forward-looking statements
to reflect events, trends or circumstances after the date they are
made unless the Company has an obligation under U.S. federal
securities laws to do so.
Investor Contact
Charles Y. Huang, MBADirector of Capital Markets
and Investor RelationsOffice: (202)-209-5751 | Direct
(301)-728-7222chuang@plustherapeutics.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
Von Dez 2023 bis Dez 2024